

Jamjoom Pharmaceuticals Factory Company Voting Results on the Agenda Items of the Extraordinary General Assembly Meeting (First Meeting), that was held on Tuesday 27/11/1445H corresponding to 4/06/2024G.

1. The Company Board of Directors' report for the financial year ending 31/12/2023 was reviewed and discussed.
2. Approval on the Company's Auditor's report for the fiscal year ended 31/12/2023.
3. The Company's financial statements for the fiscal year ending 31/12/2023 were reviewed and discussed.
4. Approval on absolving the liabilities of the members of the Board of Directors for the fiscal year ended 31/12/2023.
5. Approval on increasing the audit fees for KPMG Professional Consulting, based on the recommendation of the Audit Committee, to examine, review and audit the financial statements and data for the second, third quarters and the annual financial statements for the fiscal year 2023, as well as the first quarter for the fiscal year 2024. This increase is attributed to the reasons provided by the auditors, which are: 1- The increase in the Company's operations, hence the increase in the size of samples and the necessary procedures to be carried out, including additional examination procedures to cover high risks and the time taken to obtain examination requirements. 2- Discussions with the executive management regarding the audit differences discovered during the audit process, which took additional time and effort by the auditors until they were resolved with the management. 3- Technical query regarding the International Financial Reporting Standard (IFRS) 15, which includes preparation and gathering of all information and facts, research, discussion, and final conclusion. The initially approved fees amount to 500,000 Saudi Riyals, the increase amount is 175,000 Saudi Riyals, with a percentage increase of 35%, concluding to a total fee of 675,000 Saudi Riyals.
6. Approval of the appointment of KPMG Professional Services as the external auditor for the Company from among the candidates and based on the Audit Committee's recommendation, to examine, review and audit the financial statements and data for the second, third quarters and the annual financial statements for the fiscal year 2024, as well as the first quarter for the fiscal year 2025, and the total fees of 725,000 SAR excluding VAT.
7. Non approval on the remuneration for the members of the Board of Directors and the Committees emanating from the Board of Directors, amounting to 2,324,500 Saudi Riyals for the fiscal year ended 31/12/2023.
8. Approval of the Board of Directors' recommendation to distribute cash dividends in the amount of (105,000,000) one hundred and five million Saudi Riyals to shareholders for the second half of the year 2023G, at a rate of SAR 1.5 per share (equivalent to 15% of the nominal value of the share) in addition to what was distributed for the first half of the year 2023G in the amount of SAR (70,000,000) seventy million Saudi Riyals, thus the total dividends distributed and proposed to be distributed for the year ending on 31/12/2023G is SAR (175,000,000) one hundred and seventy five million Saudi Riyals (equivalent to 25% of the nominal value of the share) and amounting to SAR 2.5 per share. The entitlement will be for shareholders owning shares at the end of the trading day of the General Assembly, and registered in the Company's shareholder register at the Securities Depository Center (Edaa) at the end of the second trading day following the entitlement date, Note that the date of dividend distribution will on Thursday 13/6/2024 corresponding to 7/12/1445 H.
9. Approval of authorizing the Board of Directors to distribute interim dividends on a semi/quarterly basis for the fiscal year 2024.
10. Approval of amending Article (3) of the Company's bylaws basic statute related to the (purposes of the Company).

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ٤٠٣٠١٥٤٥٩٦

عنوان المصنع : رقم القطعة م . ي : ١ ، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٢٦٢٧ ، جدة - ٢١٤٤٢ ، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



11. Approval of adding Article (11) to the Company's bylaws related to (the Company's purchase of its shares and shares allocated to employees).
12. Approval of amending Article (eleventh) of the Company's bylaws related to (capital increase) and renumbering it to Article (Twelve).
13. Approval of the Company's shareholder rights policy.
14. Approval on the contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest in, and the Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves a sales agreement for pharmaceutical products to be distributed to customers under prevailing commercial terms without preferential benefits, noting that the contractual transaction value for the year 2023 amounted to 609,295,532 Saudi Riyals.
15. Approval on the contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest in, and the Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This pertains to the distribution commission based on the distribution agreement for pharmaceutical products to be distributed to customers without preferential benefits, noting that the distribution commission value for the year 2023 amounted to 3,146,333 Saudi Riyals.
16. Approval on the contracts and dealings conducted between the Company and Jamjoom Printing Establishment, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has a direct interest as the sole owner. While the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom, Ms. Alaa Yousuf Jamjoom have an indirect interest. This includes providing printing services, particularly packaging materials (publications), under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 7,424,023 Saudi Riyals.
17. Approval on the contracts and dealings conducted between the Company and Jamjoom General Agencies, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest in. While the board member Mr. Yousuf Mohammed Salah Jamjoom, has an indirect interest. This involves procuring brand reminder items under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 444,515 Saudi Riyals.
18. Non approval of the contracts and dealings conducted between the Company and Tegan Al-Fateh Factory Company Limited, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves an agreement to provide printing services (small cardboard boxes for medicines) under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 20,529,024 Saudi Riyals.
19. Non approval of the contracts and dealings conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 11,244,436 Saudi Riyals.

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ١٥٤٥٩٦-٢٠٢٤

عنوان المصنع : رقم القطعة م . ي : ١ ، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٢٢٦٧، جدة - ٢٤٤٢، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222

Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088

E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



20. Non approval of the contracts and dealings that will be conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing advance payments for the year 2024 for travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 11,244,436 Saudi Riyals, and an advance payment of 4,553,644 Saudi Riyals has been paid for transaction for the year 2024.
21. Non approval of the contracts and dealings that took place between the Company and Jamjoom Algeria Lidawa, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and the Board Member Mr. Mohammed Yousuf Jamjoom, have an indirect interest. These transactions are for the purpose of operational expenses for the joint venture, under prevailing commercial terms and without preferential benefits, noting that the value of expenses for the year 2023 amounted to 821,147 Saudi Riyals.

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ١٥٤٥٩٦-٤٠٣٠

عنوان المصنع : رقم القطعة م . ي ١ : ٣، المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي: ١٢٦٧، جدة - ٢١٤٤٢، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.

